You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile of LynAlready a subscriber Login You have read all your free articles, to continue reading subscribe…
Positive safety and efficacy data from a Phase IIb study evaluating benralizumab has been published, announces AstraZeneca. The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, Already a subscriber Login You have read all your free…
Moberg Pharma has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application and that a No Objection Letter has been received from Health Canada to begin its Phase 3 trial for MOB-015 in the treatment of onychomycosis. This Already a subscriber Login…
Medivir AB announces that the development of AL-704 (also known as JNJ-54257099) has been terminated following completion of phase I clinical studies conducted by Alios Biopharma Inc., one of the Janssen Pharmaceutical Companies. These studies demonstrated that AL-704 was safe, well tolerated andAlready a subscriber Login You have read all…
